JPWO2021230247A1 - - Google Patents
Info
- Publication number
- JPWO2021230247A1 JPWO2021230247A1 JP2021573247A JP2021573247A JPWO2021230247A1 JP WO2021230247 A1 JPWO2021230247 A1 JP WO2021230247A1 JP 2021573247 A JP2021573247 A JP 2021573247A JP 2021573247 A JP2021573247 A JP 2021573247A JP WO2021230247 A1 JPWO2021230247 A1 JP WO2021230247A1
- Authority
- JP
- Japan
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70503—Immunoglobulin superfamily
- C07K14/70539—MHC-molecules, e.g. HLA-molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/10—Peptides having 12 to 20 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4242—Transcription factors, e.g. SOX or c-MYC
- A61K40/4243—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
- A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/804—Blood cells [leukemia, lymphoma]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Hematology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Cell Biology (AREA)
- Virology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022149790A JP7209986B2 (ja) | 2020-05-12 | 2022-09-21 | 癌を処置するための医薬組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2020083905 | 2020-05-12 | ||
| JP2020083905 | 2020-05-12 | ||
| PCT/JP2021/017929 WO2021230247A1 (ja) | 2020-05-12 | 2021-05-11 | 癌を処置するための医薬組成物 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022149790A Division JP7209986B2 (ja) | 2020-05-12 | 2022-09-21 | 癌を処置するための医薬組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2021230247A1 true JPWO2021230247A1 (https=) | 2021-11-18 |
| JP7153287B2 JP7153287B2 (ja) | 2022-10-14 |
Family
ID=78524529
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573247A Active JP7153287B2 (ja) | 2020-05-12 | 2021-05-11 | 癌を処置するための医薬組成物 |
| JP2022149790A Active JP7209986B2 (ja) | 2020-05-12 | 2022-09-21 | 癌を処置するための医薬組成物 |
| JP2022209886A Active JP7248261B2 (ja) | 2020-05-12 | 2022-12-27 | 癌を処置するための医薬組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022149790A Active JP7209986B2 (ja) | 2020-05-12 | 2022-09-21 | 癌を処置するための医薬組成物 |
| JP2022209886A Active JP7248261B2 (ja) | 2020-05-12 | 2022-12-27 | 癌を処置するための医薬組成物 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20230183316A1 (https=) |
| EP (1) | EP4151227A4 (https=) |
| JP (3) | JP7153287B2 (https=) |
| KR (1) | KR20230009426A (https=) |
| CN (1) | CN115867303A (https=) |
| AU (1) | AU2021272616A1 (https=) |
| CA (1) | CA3182959A1 (https=) |
| MX (1) | MX2022014249A (https=) |
| TW (1) | TW202200188A (https=) |
| WO (1) | WO2021230247A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN116970059A (zh) | 2016-12-22 | 2023-10-31 | 库尔生物制药有限公司 | T细胞调节性多聚体多肽及其使用方法 |
| WO2021055594A1 (en) * | 2019-09-20 | 2021-03-25 | Cue Biopharma, Inc. | T-cell modulatory polypeptides and methods of use thereof |
| TW202208395A (zh) | 2020-05-12 | 2022-03-01 | 美商信號生物製藥公司 | 多聚體ｔ細胞調節多肽及其使用方法 |
| AU2022327884A1 (en) * | 2021-08-12 | 2024-02-22 | International Institute Of Cancer Immunology, Inc. | Pharmaceutical composition and method for treatment or prevention of cancer |
| CN121015864B (zh) * | 2025-10-31 | 2026-02-03 | 可蓝赛生物医药(上海)有限公司 | 一种含有多糖佐剂的肿瘤疫苗及其应用 |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005001117A1 (ja) * | 2003-06-27 | 2005-01-06 | Haruo Sugiyama | Ｗｔ１ワクチン適応患者の選択方法 |
| JP2007515393A (ja) * | 2003-04-30 | 2007-06-14 | コリクサ コーポレイション | Ｗｔ１特異的な免疫治療のための組成物および方法 |
| JP2007516966A (ja) * | 2003-12-01 | 2007-06-28 | スローン−ケターリング インスティチュート フォー キャンサー リサーチ | 合成ｈｌａ結合ペプチド類似体及びその使用方法 |
| WO2008081701A1 (ja) * | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 |
| WO2014157692A1 (ja) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| JP2016530290A (ja) * | 2013-09-06 | 2016-09-29 | アルティミューン ユーケー リミテッド | 腫瘍学ワクチン |
| WO2018101309A1 (ja) * | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BE555319A (https=) | 1956-03-21 | 1900-01-01 | ||
| US3095355A (en) | 1961-10-12 | 1963-06-25 | Revlon | Aerosol composition |
| US5840839A (en) * | 1996-02-09 | 1998-11-24 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein |
| CN1560078B (zh) | 1998-07-31 | 2011-06-22 | 株式会社国际癌症免疫研究所 | 基于癌抑制基因wt1的产物的癌抗原 |
| US20030072767A1 (en) | 1998-09-30 | 2003-04-17 | Alexander Gaiger | Compositions and methods for WT1 specific immunotherapy |
| ATE399179T1 (de) | 1998-09-30 | 2008-07-15 | Corixa Corp | Zusammensetzungen und verfahren für wt1- spezifische immunotherapie |
| US20030235557A1 (en) | 1998-09-30 | 2003-12-25 | Corixa Corporation | Compositions and methods for WT1 specific immunotherapy |
| US20050050580A1 (en) | 2000-12-13 | 2005-03-03 | Masashi Gotoh | Transgenic animal expressing hla-a24 and utilization thereof |
| ES2298353T3 (es) | 2001-03-22 | 2008-05-16 | International Institute Of Cancer Immunology, Inc. | Peptido wt1 modificado. |
| WO2003106682A1 (ja) | 2002-06-12 | 2003-12-24 | 中外製薬株式会社 | Ｈｌａ−ａ２４拘束性癌抗原ペプチド |
| ATE442378T1 (de) | 2002-09-20 | 2009-09-15 | Int Inst Cancer Immunology Inc | Substituierte wt1-peptide |
| US7353321B2 (en) | 2003-01-13 | 2008-04-01 | Sierra Logic | Integrated-circuit implementation of a storage-shelf router and a path controller card for combined use in high-availability mass-storage-device shelves that may be incorporated within disk arrays |
| CN101580538B (zh) | 2003-11-05 | 2013-06-19 | 株式会社国际癌症免疫研究所 | Wt1衍生的hla-dr-结合抗原肽 |
| WO2006078059A1 (ja) | 2005-01-19 | 2006-07-27 | Dainippon Sumitomo Pharma Co., Ltd. | 希釈用乳化組成物および癌ワクチン組成物 |
| ES2542141T3 (es) | 2005-10-17 | 2015-07-31 | Sloan Kettering Institute For Cancer Research | Péptidos WT1 de unión a HLA de clase II, y composiciones y métodos que los comprenden |
| ES2352855T3 (es) | 2005-11-30 | 2011-02-23 | International Institute Of Cancer Immunology, Inc. | Nuevos compuestos peptídicos del tumor de wilms. |
| PL2010209T3 (pl) | 2006-04-10 | 2017-04-28 | Sloan Kettering Inst For Cancer Res | Immunogeniczne peptydy WT-1 i sposoby ich użycia |
| ES2679127T3 (es) | 2007-12-05 | 2018-08-22 | International Institute Of Cancer Immunology, Inc. | Composición vacunal contra el cáncer |
| WO2010037395A2 (en) | 2008-10-01 | 2010-04-08 | Dako Denmark A/S | Mhc multimers in cancer vaccines and immune monitoring |
| AR076349A1 (es) | 2009-04-23 | 2011-06-01 | Int Inst Cancer Immunology Inc | Peptido auxiliar del antigeno del cancer |
| BR112012029066A2 (pt) * | 2010-05-14 | 2020-09-01 | The General Hospital Corporation | composições e processos de identificação de neoantígenos específicos de tumor. |
| WO2012044999A2 (en) * | 2010-10-01 | 2012-04-05 | Ludwig Institute For Cancer Research Ltd. | Reversible protein multimers, methods for their production and use |
| EP3155426B1 (en) * | 2014-06-13 | 2023-07-19 | Immudex ApS | General detection and isolation of specific cells by binding of labeled molecules |
| JP6515182B2 (ja) * | 2015-05-20 | 2019-05-15 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドおよび免疫調節剤の併用 |
| AU2018366131A1 (en) * | 2017-11-08 | 2020-05-28 | Advaxis, Inc. | Immunogenic heteroclitic peptides from cancer-associated proteins and methods of use thereof |
| US20210213066A1 (en) * | 2018-05-18 | 2021-07-15 | Children's National Medical Center | Improved cell therapy compositions for hematopoietic stem cell transplant patients |
| JP7213067B2 (ja) | 2018-11-15 | 2023-01-26 | 花王株式会社 | ポリマーエマルションの製造方法 |
-
2021
- 2021-05-11 WO PCT/JP2021/017929 patent/WO2021230247A1/ja not_active Ceased
- 2021-05-11 KR KR1020227042759A patent/KR20230009426A/ko active Pending
- 2021-05-11 CN CN202180049519.7A patent/CN115867303A/zh active Pending
- 2021-05-11 AU AU2021272616A patent/AU2021272616A1/en active Pending
- 2021-05-11 MX MX2022014249A patent/MX2022014249A/es unknown
- 2021-05-11 TW TW110116866A patent/TW202200188A/zh unknown
- 2021-05-11 CA CA3182959A patent/CA3182959A1/en active Pending
- 2021-05-11 JP JP2021573247A patent/JP7153287B2/ja active Active
- 2021-05-11 EP EP21804472.5A patent/EP4151227A4/en active Pending
- 2021-05-11 US US17/998,430 patent/US20230183316A1/en active Pending
-
2022
- 2022-09-21 JP JP2022149790A patent/JP7209986B2/ja active Active
- 2022-12-27 JP JP2022209886A patent/JP7248261B2/ja active Active
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2007515393A (ja) * | 2003-04-30 | 2007-06-14 | コリクサ コーポレイション | Ｗｔ１特異的な免疫治療のための組成物および方法 |
| WO2005001117A1 (ja) * | 2003-06-27 | 2005-01-06 | Haruo Sugiyama | Ｗｔ１ワクチン適応患者の選択方法 |
| JP2007516966A (ja) * | 2003-12-01 | 2007-06-28 | スローン−ケターリング インスティチュート フォー キャンサー リサーチ | 合成ｈｌａ結合ペプチド類似体及びその使用方法 |
| WO2008081701A1 (ja) * | 2006-12-28 | 2008-07-10 | International Institute Of Cancer Immunology, Inc. | Ｈｌａ－ａ＊１１０１拘束性ｗｔ１ペプチド、およびそれを含む医薬組成物 |
| WO2014157692A1 (ja) * | 2013-03-29 | 2014-10-02 | 大日本住友製薬株式会社 | Ｗｔ１抗原ペプチドコンジュゲートワクチン |
| JP2016530290A (ja) * | 2013-09-06 | 2016-09-29 | アルティミューン ユーケー リミテッド | 腫瘍学ワクチン |
| WO2018101309A1 (ja) * | 2016-11-30 | 2018-06-07 | 大日本住友製薬株式会社 | Ｗｔ１ヘルパーペプチド及びこれと癌抗原ペプチドコンジュゲート体との組合せ |
| WO2019131722A1 (ja) * | 2017-12-27 | 2019-07-04 | 大日本住友製薬株式会社 | Ｗｔ１由来ペプチドのコンジュゲート体およびこれを含む組成物 |
Non-Patent Citations (1)
| Title |
|---|
| TADA Y.ET AL.: "Analysis of cytotoxic T lymphocytes from a patient with hepatocellular carcinoma who showed a clinic", INTERNATIONAL JOURNAL OF ONCOLOGY, vol. 43, JPN6021022734, 2013, pages 1019 - 1026, ISSN: 0004794121 * |
Also Published As
| Publication number | Publication date |
|---|---|
| AU2021272616A1 (en) | 2022-12-15 |
| TW202200188A (zh) | 2022-01-01 |
| JP7153287B2 (ja) | 2022-10-14 |
| US20230183316A1 (en) | 2023-06-15 |
| KR20230009426A (ko) | 2023-01-17 |
| CN115867303A (zh) | 2023-03-28 |
| WO2021230247A1 (ja) | 2021-11-18 |
| CA3182959A1 (en) | 2021-11-18 |
| JP7248261B2 (ja) | 2023-03-29 |
| EP4151227A1 (en) | 2023-03-22 |
| JP2022180513A (ja) | 2022-12-06 |
| JP2023036884A (ja) | 2023-03-14 |
| JP7209986B2 (ja) | 2023-01-23 |
| MX2022014249A (es) | 2023-02-22 |
| EP4151227A4 (en) | 2025-01-15 |
Similar Documents
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20211209 |
|
| A871 | Explanation of circumstances concerning accelerated examination |
Free format text: JAPANESE INTERMEDIATE CODE: A871 Effective date: 20211209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220222 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220421 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20220607 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220803 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20220823 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20220921 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7153287 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313117 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |